BRONXIAL ASTMADA EOZINOFILLAR MIQDORI VA KASALLIK OG‘IRLIGI O‘RTASIDAGI BOG‘LIQLIK
Keywords:
Bronxial astma, eozinofillar, qon eozinofillari, Type 2 yallig‘lanish, og‘ir astma, zo‘rayish, FeNO, biologik terapiya.Abstract
Bronxial astma nafas yo‘llarining surunkali yallig‘lanishi va o‘zgaruvchan havo oqimi cheklanishi bilan kechuvchi heterogen kasallikdir. Eozinofillar Type 2 yallig‘lanishining asosiy hujayraviy belgilaridan biri bo‘lib, ularning periferik qondagi miqdori astma zo‘rayishlari xavfini va ayrim bemorlarda kasallikning og‘ir, nazorat qilinmaydigan fenotipini aniqlashda muhim biomarker hisoblanadi. Yevropa va Shimoliy Amerikada o‘tkazilgan yirik kohort tadqiqotlari hamda meta-tahlillar eozinofillar soni oshgani sari og‘ir zo‘rayishlar, shoshilinch yordamga murojaat qilish va kasallik nazoratining yomonlashishi ehtimoli ortishini ko‘rsatgan. Biroq qon eozinofillari astma og‘irligining mustaqil va yagona mezoni emas. Ularni simptomlar nazorati, avvalgi zo‘rayishlar, o‘pka funksiyasi, FeNO va davolashga javob bilan birgalikda baholash zarur. Ushbu maqolada qon eozinofillari miqdori bilan astma og‘irligi o‘rtasidagi klinik bog‘liqlik va uning amaliy ahamiyati tahlil qilinadi.
References
1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2025 Update. GINA; 2025.
2. Global Initiative for Asthma. Difficult-to-Treat & Severe Asthma in Adolescent and Adult Patients: Diagnosis and Management. GINA; 2025.
3. Prazma CM, et al. Blood eosinophil count as predictor of asthma exacerbation: A meta-analysis. Allergy. 2021;76(5):1282–1292.
4. Price DB, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med. 2015;3(11):849–858.
5. Price DB, et al. Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice. J Asthma Allergy. 2016;9:1–12.
6. Israel E, et al. Blood Eosinophil Count and Outcomes in Severe Uncontrolled Asthma: A Prospective Study. J Allergy Clin Immunol. 2016;138(3):779–786.
7. Holguin F, et al. Management of severe asthma: an American Thoracic Society/European Respiratory Society guideline. Eur Respir J. 2020;55(1):1900588.
8. McDowell PJ, et al. Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials. Lancet Respir Med. 2025.